Mar
30
2023
On demand
A platform approach to tackling AAV potency
Thursday 09:37 BST / 10:37 CEST / 10:37 EET / 11:37 EAT / 12:37 +04
Sponsor
AAV gene therapy products have complex mechanisms of action that pose unique challenges to potency assay development. Determining the true biological activity often requires multiple assays (i.e., a matrix approach), and the strategy for implementing these assays may evolve throughout the product lifecycle.
Join us as we discuss our strategy for potency assay development and how a platform approach can set you up for success.
- Hear about common challenges in AAV potency development
- What is a matrix approach?
- Learn about our platform methods that enable rapid development of phase-appropriate potency assays.
SPEAKERS
You might also like
Producing engineered extracellular vesicles with a platform approach
Sriram Sathy, Vijetha Bhat
13 February
Watch
Characterization and release testing for AAV therapies: empty/partial/full capsid analysis and impact on potency
K Doucette, F Vass, K Bertram
25 July 2024
Watch
From concept to clinic: overcoming the challenges of potency assays in cell and gene therapy development
Audrey Chang, Joe Newcome
10 December 2024
Watch
Development of an automated AAV capsid titer assay on a high-throughput platform
Matthew J.Lotti, John Chappell
3 September 2024
Watch
Big pharma case study: alpha testing of a generic anti-AAV kit and comparison to in-house methods
Kira Hedström, Eva-Maria Thüring
30 January
Watch